Han L - Search Results

1

High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.

Zhao Y, Du X, Duan Y, Pan X, Sun Y, You T, Han L, Jin Z, Shang W, Yu J, Guo H, Liu Q, Wu Y, Peng C, Wang J, Zhu C, Yang X, Yang K, Lei Y, Guddat LW, Xu W, Xiao G, Sun L, Zhang L, Rao Z, Yang H. Zhao Y, et al. Among authors: han l. Protein Cell. 2021 Nov;12(11):877-888. doi: 10.1007/s13238-021-00836-9. Epub 2021 Apr 17. Protein Cell. 2021. PMID: 33864621 Free PMC article.

2

Self-Assembled Tumor-Penetrating Peptide-Modified Poly(l-γ-glutamylglutamine)-Paclitaxel Nanoparticles Based on Hydrophobic Interaction for the Treatment of Glioblastoma.

Yu J, Sun L, Zhou J, Gao L, Nan L, Zhao S, Peng T, Han L, Wang J, Lu W, Zhang L, Wang Y, Yan Z, Yu L. Yu J, et al. Among authors: han l. Bioconjug Chem. 2017 Nov 15;28(11):2823-2831. doi: 10.1021/acs.bioconjchem.7b00519. Epub 2017 Oct 10. Bioconjug Chem. 2017. PMID: 28968068

3

A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding.

Wang Y, Zhan W, Liu J, Wang Y, Zhang X, Zhang M, Han L, Ma Y, Lu L, Wen Y, Chen Z, Zhao J, Wu F, Sun L, Huang J. Wang Y, et al. Among authors: han l. Cell Res. 2022 Sep;32(9):862-865. doi: 10.1038/s41422-022-00684-0. Epub 2022 Jun 29. Cell Res. 2022. PMID: 35768499 Free PMC article. No abstract available.

4

Expression, purification, and microscopic characterization of the tumor suppressor KLHL6.

Han L, Chen Z, Sun L. Han L, et al. Protein Expr Purif. 2023 Oct;210:106318. doi: 10.1016/j.pep.2023.106318. Epub 2023 Jun 5. Protein Expr Purif. 2023. PMID: 37286065

5

IL-1β Enhances the Antiviral Effect of IFN-α on HCV Replication by Negatively Modulating ERK2 Activation.

Guo M, Ye L, Yu T, Han L, Li Q, Lou P, Gan T, Jin X, Xiao H, Meng G, Zhong J, Xu Y. Guo M, et al. Among authors: han l. ACS Infect Dis. 2020 Jul 10;6(7):1708-1718. doi: 10.1021/acsinfecdis.9b00506. Epub 2020 Jun 1. ACS Infect Dis. 2020. PMID: 32420725

6

Photo-catalyzed TiO₂ inactivates pathogenic viruses by attacking viral genome.

Tong Y, Shi G, Hu G, Hu X, Han L, Xie X, Xu Y, Zhang R, Sun J, Zhong J. Tong Y, et al. Among authors: han l. Chem Eng J. 2021 Jun 15;414:128788. doi: 10.1016/j.cej.2021.128788. Epub 2021 Feb 3. Chem Eng J. 2021. PMID: 33558800 Free PMC article.

7

Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.

Leumi S, Guo M, Lu J, Wang Z, Gan T, Han L, Ngari J, Tong Y, Xiang X, Xie Q, Wang L, Zhong J. Leumi S, et al. Among authors: han l. Antiviral Res. 2022 Jan;197:105224. doi: 10.1016/j.antiviral.2021.105224. Epub 2021 Dec 2. Antiviral Res. 2022. PMID: 34864126

8

Neuralized E3 Ubiquitin Protein Ligase 3 Is an Inducible Antiviral Effector That Inhibits Hepatitis C Virus Assembly by Targeting Viral E1 Glycoprotein.

Zhao Y, Cao X, Guo M, Wang X, Yu T, Ye L, Han L, Hei L, Tao W, Tong Y, Xu Y, Zhong J. Zhao Y, et al. Among authors: han l. J Virol. 2018 Oct 12;92(21):e01123-18. doi: 10.1128/JVI.01123-18. Print 2018 Nov 1. J Virol. 2018. PMID: 30111563 Free PMC article.

9

Anti-flavivirus activity of polyoxometalate.

Qi Y, Han L, Qi Y, Jin X, Zhang B, Niu J, Zhong J, Xu Y. Qi Y, et al. Among authors: han l. Antiviral Res. 2020 Jul;179:104813. doi: 10.1016/j.antiviral.2020.104813. Epub 2020 May 4. Antiviral Res. 2020. PMID: 32376449

10

Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon.

Ngari JW, Leumi S, Han L, Liu C, Tong Y, Zhong J. Ngari JW, et al. Among authors: han l. J Med Virol. 2023 Dec;95(12):e29290. doi: 10.1002/jmv.29290. J Med Virol. 2023. PMID: 38102947

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12,472 results

Search Page